# Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension

> **NCT03814148** · PHASE3 · WITHDRAWN · sponsor: **EMS**

## Conditions studied

- Arterial Hypertension

## Interventions

- **DRUG:** LENINGRADO 5 association
- **DRUG:** Natrilix® SR
- **OTHER:** Natrilix SR Placebo
- **OTHER:** Leningrado 5 association Placebo

## Key facts

- **NCT ID:** NCT03814148
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06
- **Primary completion:** 2020-06
- **Final completion:** 2020-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The design of this protocol was rewritten due to regulatory recommendations.
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03814148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03814148, "Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03814148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*